Dec. 7, 2022
- Qurgen has obtained the FDA approval for a first-in-human Phase I clinical trial IND application for an anti-cancer transcription factor protein drug, SON-DP, for the treatment of the patients with late-stage solid tumors with the focus on: Breast Cancer including triple negative breast cancer, Ovary Cancer, Pancreatic Cancer and Colorectal Cancer.